RedHill Biopharma (RDHL) Assets Average (2016 - 2025)
Historic Assets Average for RedHill Biopharma (RDHL) over the last 13 years, with Q2 2025 value amounting to $18.2 million.
- RedHill Biopharma's Assets Average fell 1919.86% to $18.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.2 million, marking a year-over-year decrease of 1919.86%. This contributed to the annual value of $20.5 million for FY2024, which is 7741.28% down from last year.
- Latest data reveals that RedHill Biopharma reported Assets Average of $18.2 million as of Q2 2025, which was down 1919.86% from $20.0 million recorded in Q4 2024.
- In the past 5 years, RedHill Biopharma's Assets Average registered a high of $211.9 million during Q2 2021, and its lowest value of $18.2 million during Q2 2025.
- Moreover, its 5-year median value for Assets Average was $160.3 million (2022), whereas its average is $121.3 million.
- As far as peak fluctuations go, RedHill Biopharma's Assets Average skyrocketed by 8400.86% in 2021, and later crashed by 8162.26% in 2023.
- Quarter analysis of 5 years shows RedHill Biopharma's Assets Average stood at $183.8 million in 2021, then fell by 14.0% to $158.0 million in 2022, then tumbled by 81.62% to $29.0 million in 2023, then crashed by 31.02% to $20.0 million in 2024, then decreased by 9.11% to $18.2 million in 2025.
- Its Assets Average stands at $18.2 million for Q2 2025, versus $20.0 million for Q4 2024 and $22.5 million for Q2 2024.